Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Myelodysplastic Syndromes 159Leukemia, Myeloid, Acute 141Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Myeloproliferative Disorders 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Primary Myelofibrosis 47Leukemia, Myelomonocytic, Chronic 40Lymphoma, Non-Hodgkin 36Leukemia 26Polycythemia Vera 23Hodgkin Disease 23Myelodysplastic-Myeloproliferative Diseases 21Multiple Myeloma 20Thrombocythemia, Essential 19Hematologic Neoplasms 19Leukemia, Lymphocytic, Chronic, B-Cell 18Neoplasms 17Leukemia, Biphenotypic, Acute 15Anemia, Refractory, with Excess of Blasts 14Sarcoma 13Histiocytosis, Langerhans-Cell 13Glioma 13Neuroblastoma 12Hematologic Diseases 12Wilms Tumor 11Rhabdoid Tumor 11Recurrence 11Osteosarcoma 11Neuroectodermal Tumors, Primitive, Peripheral 11Medulloblastoma 11

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Mesothelial × Myeloid × 90 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡